Use of Glucagon in the Treatment of Pancreatitis

Knight, Michael; Condon, John R.; Smith, R. D.

doi:10.1136/bmj.2.5759.440

Cited by 78 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this purpose several hormones with inhibitory effects on the pancreas have been recommended, such as glucagon (Zajtchuk et al, 1967;Dyck et al, 1970), calcitonin (Schmidt et al, 1971), and SRIF , which all markedly depress the ecbolic and to a lesser extent the hydrokinetic pancreatic secretion. Knight et al (1971) first introduced glucagon in the treatment of acute pancreatitis and this was followed by several reports in favour of this new therapy.…”

Section: Discussionmentioning

confidence: 99%

Somatostatin therapy of acute experimental pancreatitis.

Lankisch¹,

Koop²,

Winckler³

et al. 1977

Gut

View full text Add to dashboard Cite

SUMMARY Because somatostatin (SRIF) reduces exocrine pancreatic secretion, its effect on acute pancreatitis was investigated in rats. Linear SRIF reduced serum amylase and lipase but had no effect on pancreatic necrosis, oedema, leucocyte infiltration, and enzyme content. The mortality rate was not reduced. These results do not recommend the use of SRIF in the treatment of acute pancreatitis.Cyclic somatostatin (SRIF) significantly reduces hormonal Dollinger et al., 1976;Domschke et al., 1976) and non-hormonal stimulated pancreatic volume and enzyme secretion in man. Linear SRIF inhibits basal and hormonal stimulated enzyme secretion in the rat (Folsch et al., 1976). As 'rest to the gland' is generally considered to be a major aim in the treatment of acute pancreatitis (Trapnell, 1972) the effect of SRIF was investigated in acute experimental pancreatitis in the rat. MethodsAcute experimental pancreatitis was induced by retrograde injection of 0-6 ml of 0-8, 2-0, 2-5, and 3-0 Na-taurocholate (Serva Feinbiochemica, Heidelberg) into the pancreatic ducts of 101 male Wistar rats (180-220 g) (Lankisch et al., 1974). Linear SRIF (Serono, Freiburg) was given subcutaneously at a dosage of 200 ,ug during operation as a bolus injection followed by infusion of 100 ,ug/100 g body weight/h for three hours. This regime had been found to decrease significantly pancreatic enzyme secretion for more than four hours (Folsch et al., 1976). Controls received saline infusions. To investigate the SRIF influence upon the survival rate the following groups were formed (Figure) : (a) SRIFtherapy: n = 6; (b) controls: n = 5; 0-8 %-Na-taurocholate-pancreatitis was not used for survival experiments as the mortality rate of this model is too low to demonstrate the success of a treatment.To study the effects of SRIF upon morphological and enzymatic factors rats were killed four hours after induction of pancreatitis by 0-8, 2-0, and 3 0%-Na-taurocholate-that is, one hour after the treatment was stopped. 2 5%-Na-taurocholate-pancreatitis was not used as there were no distinct differences between 2-0 and 3 0 %-Na-taurocholate-pancreatitis where the above mentioned factors were concerned (Table). Ascites was measured and tissue from the head and the tail of the pancreas was fixed in Bouin's solution, embedded in paraffin, cut in 5 ,um sections, and stained with haematoxylin and eosin.

show abstract

Section: Discussionmentioning

confidence: 99%

Somatostatin therapy of acute experimental pancreatitis.

Lankisch¹,

Koop²,

Winckler³

et al. 1977

Gut

View full text Add to dashboard Cite

show abstract

“…Glucagon inhibition of exocrine pancreatic function has previously been reported in man (7,17) and in animals (11)(12)(13)(14)(15). To date all secretory studies in man have been carried out in subjects free of pancreatic disease using a bolus dose of glucagon.…”

mentioning

confidence: 99%

Glucagon Inhibition of Secretin and Combined Secretin and Cholecystokinin Stimulated Pancreatic Exocrine Secretion in Health and Disease

Clain¹,

Barbezat²,

Waterworth³

et al. 1978

Digestion

View full text Add to dashboard Cite

show abstract

“…Various agents which suppress pancreatic secretion have been used in the treatment of acute pancreatitis (2,4). One measure of the efficacy of these agents is their ability to lower the serum amylase values (12).…”

mentioning

confidence: 99%